Background and Importance Cannabidiol is approved in Europe as adjunctive therapy for preventing seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS), and Tuberous Sclerosis Complex (TSC) in patients with previous treatment refractory epilepsy.

Aim and Objectives This study aims to evaluate the efficacy and safety of cannabidiol in a cohort of patients from a medium-sized hospital.

Material and Methods An observational retrospective study was conducted. Patients diagnosed with LGS and DS who began treatment with cannabidiol from October 2019 to September 2023 were included. Data collected were demographics (gender, age), drug therapy (number of concomitant drugs) and clinical outcomes (Reduction > 50% on seizure rate and cannabidiol side effects).

Results Ten patients were included on the analysed data set, with a mean age of 32.8 years, nine of them had LGS associated epilepsy, and one to DS. With a median treatment duration of 633 days and a cannabidiol median dose of 10,49 mg/Kg/day, 70% of patients reached a seizure reduction > 50%, being the majority of them out of drug related side effects.

Conclusion and Relevance As a real-life experience, our findings confirm that the safety and efficacy profiles of cannabidiol showed by the trials GWPCARE3 and GWPCARE4 (mean age=15 years)¹are extended to our local adult population with a higher average age of 32.8 years.

References and/or Acknowledgements 1. epidyolex-epar-product-information_en.pdf (https://www.ema.europa.eu/en/documents/product-information/epidyolex-epar-product-information_en.pdf)

Conflict of Interest No conflict of interest.